Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10690594 | 0.71 | ALDH1A1 (0.33) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL1395705 | 0.60 | — | — | |
| SCHEMBL9324824 | 0.60 | CYP2A6 (0.35) | CYP2A6ALOX12 | |
| SCHEMBL132970 | 0.60 | CYP2A6 (0.35) | CYP2A6ALOX12 | |
| SCHEMBL9196 | 0.60 | MAPT (0.36) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL23499930 | 0.56 | NPC1 (0.39) | CYP2A6 | |
| SCHEMBL24252 | 0.55 | CYP2A6 (0.41) | ALDH1A1GLAMAPTHPGDACHE | |
| SCHEMBL184780 | 0.55 | ALDH1A1 (0.32) | ALDH1A1CYP2A6ALOX12 | |
| Phthalazine SCHEMBL22439995 | 0.55 | CYP2A6 (0.50) | ALDH1A1GLAMAPTHPGDACHE | |
| Phthalazine SCHEMBL29356700 | 0.55 | CYP2A6 (0.50) | ALDH1A1GLAMAPTHPGDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-2883865-B1 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO (JP) | 2019-09-25 | — | — | EP | disclosed |
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | disclosed |
| EP-2883865-A1 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-17 | — | — | EP | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| EP-1661881-B1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2805937-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-20090018264-A1 | RESIN COMPOSITION | CANON KABUSHIKI KAISHA (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
| CN-1874991-A | Compounds capable of binding to the S1P receptor and pharmaceutical uses thereof | ONO PHARMACEUTICAL CO (JP) | 2006-12-06 | — | — | CN | disclosed |
| EP-1661881-A2 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1173427-B1 | HYDROXAMIC ACID DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-6713477-B1 | 1,4-BENZTHIAZINES OR BENZOXAZINES; MATRIX METALLOPROTEINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-30 | — | — | US | disclosed |
| EP-1173427-A1 | HYDROXAMIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000063197-A1 | HYDROXAMIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | ALDH1A1 1108/4885GLA 3878/4885MAPT 1670/4885 |
| US-20140288034-A1 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | S1PR1, S1PR2, S1PR3 | ALDH1A1 1768/4885GLA 3365/4885MAPT 4760/4885 |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | S1PR1, S1PR3, S1PR2 | ALDH1A1 2079/4885GLA 2994/4885MAPT 4603/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | ALDH1A1 2257/4885GLA 4642/4885MAPT 4728/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | ALDH1A1 2082/4885GLA 3172/4885MAPT 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.